CTLA4 and hypophysitis: It was reported that hypophysitis can affect up to 10% of patients treated with anti‐CTLA‐4 inhibitors.2 Hepatitis occurred in 5% to 10% of patients during treatment with ipilimumab, nivolumab and pembrolizumab.4 Thyroid dysfunction occurred in 5% to 10% patients receiving PD‐1/PD‐L1 inhibitors.